肺動脈高血圧の初期治療後の追跡血液動力学的変数の予後値
Jason Weatherald1,2,3,4,5, Athénaïs Boucly6,2,3, Denis Chemla6,2,7
1Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France (J.W., A.B., D.C., L.S., M.J., X.J., Y.T., C.O., F.P., C.S., P.H., G.S., D.M., M.H., O.S.) olivier.sitbon@aphp.fr jcweathe@ucalgary.ca.
Circulation
|October 27, 2017
まとめ
脳卒中の体積指数と右心房圧は,肺動脈高血圧 (PAH) 患者の治療後のアウトカムを予測する. これらの血液動力学的測定は,PAH管理における生存と治療目標の重要な指標です.
科学分野:
- 心臓病科
- 肺高血圧 研究
- ヘモダイナミック・モニタリング
背景:
- 肺動脈高血圧 (PAH) の基礎血液動力学変数 (心臓指数,右心房圧) の確立された予後値.
- 新興の証拠は,肺動脈適合性もPAHの予後を予測する可能性があることを示唆しています.
- 治療開始後の血液動力学的値の予後的意義に関する理解は限られている.
研究 の 目的:
- 初期治療後のPAH患者の追跡期間における臨床および血液動力学的変数の予後的重要性を評価する.
- 治療されたPAHにおけるアウトカムの予測における肺動脈適合の役割を評価する.
- 治療後のPAH患者の生存のための重要な血液動力学的指標を特定する.
主な方法:
- 病原性,薬物/毒素誘発性,または遺伝性PAHの症例患者の分析 フランス肺高血圧登録 (2006年−2016年)
- 少なくとも1回のフォローアップの右側心経導管手術 (RHC) を受けた患者を含む.
- 主なアウトカム:死または肺移植 段階的なコックス回帰とカプラン・マイヤー法を用いた統計分析.
主要な成果:
- 多変量分析では,出血動力学的変数が独立して予後を予測しなかった.
- 最初のフォローアップRHCでは,ニューヨーク心臓協会の機能クラス,6分間の歩行距離,脳卒中量指数 (SVI),右心房圧は独立して死亡または肺移植と関連していました.
- 肺動脈の順守は独立して結果を予測しなかった. 下のSVIと右心房圧の上昇は,有害事象の有意な予測要因でした.
結論:
- 脳卒中の体積指数 (SVI) と右心房圧は,PAH治療後の追跡RHCで死亡または肺移植と独立して関連しています.
- これらの発見は,PAHの管理において,SVIは心臓指数よりも適切な治療目標である可能性があることを示唆しています.
- フォローアップ中の血液動力学的評価は,PAHの予後と治療の指針に不可欠です.
関連する概念動画
01:30Heart Failure V: Medical Management
381
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
381
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
494
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
494
01:25Aortic Regurgitation III: Medical Management
479
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
479
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
531
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
531
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
573
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
573
01:17Aortic Regurgitation IV: Nursing Management
333
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
333